ERBB2 and breast carcinoma: This concept is now validated following FDA approval of KadcyclaTM and AdcetrisTM, for the treatment of HER2-positive breast cancer and Hodgkin Lymphoma respectively.14,16 However, there is a recognised requirement for conjugation chemistries that yield more homogeneous ADC products and that facilitate release of the payload once the ADC has been internalised into its target cell.